Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cinacalcet Cost-Effective When “Stopping Rules” Are Applied, Amgen Contends

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE draft appraisal concludes hyperparathyroidism therapy is unlikely to be considered cost-effective.

You may also be interested in...



Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation

NICE determination limits recommended use to severe refractory SHPT patients.

Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation

NICE determination limits recommended use to severe refractory SHPT patients.

Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients

Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS064694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel